AUTHORS
Gigi Nu Hoang Quy Ton, PhD, Laura Kluge2, Shehabeldin Elzoheiry, PhD3, Kristin Schmitt4, Cheyenne Schmitt5, Murat Kara6, Sergej Medenhoff7, Carsten Mueller-Tidow, MD8, Mohamed H. S. Awwad, PhD9, Michael Hundemer, MD10
AFFILIATIONS
1 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
2 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
3 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
4 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
5 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
6 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
7 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
8 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
9 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany
10 Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Laboratory for Hematological Diagnostic, Heidelberg University Hospital Internal Medicine V, Heppenheim, Germany
ABSTRACT
Introduction: Pharmacological degradation of Ikaros zinc finger protein (IKZF) members IKZF1 and IKZF3 drives the immunomodulatory activity of IMiDs and cereblon E3 ligase modulators and is increasingly explored to enhance chimeric antigen receptor (CAR) T cell, T cell engager, and other T cell-based immunotherapies. However, emerging evidence further indicates that these agents act within a broader, interacting IKZF family network, offering additional context for their mechanism of action. How dimer composition, functional hierarchy, and compensatory family responses determine the resulting T cell state remains unknown. We investigated how IKZF family architecture shapes CD8+ T cell reprogramming and adaptation to IKZF1/IKZF3 blocking.
Methods: Stable knockdown (KD) of IKZF1, IKZF3, or both was established in primary human CD8+ T cells using lentiviral shRNA. Consequences were assessed by RNA-seq, ATAC-seq, quantitative proteomics, co-immunoprecipitation–mass spectrometry, multiparameter flow cytometry, and multiplex cytokine profiling. IKZF family interactions were mapped by GST pull-down and quantified in intact cells using reciprocal FLIM-FRET.
Results: Endogenous complex mapping established the dominant interaction within activated CD8+ T cells: IKZF3 co-immunoprecipitation–mass spectrometry recovered IKZF1 as its most abundant partner. GST pull-down localized this interaction to the conserved C-terminal zinc fingers. Reciprocal FLIM-FRET then linked individual dimer pairs to distinct subcellular patterns. IKZF1 homodimers were detected in the nucleus and also showed perinuclear and cytoplasmic signal, whereas IKZF2 and IKZF3 were predominantly nuclear. Heterodimers between IKZF1 and IKZF3 showed a punctate nuclear distribution with enrichment at foci morphologically consistent with pericentromeric heterochromatin. By contrast, heterodimers between IKZF1 and IKZF2 displayed a more diffuse nuclear pattern. These observations identify IKZF1 as a central interaction hub and demonstrate that partner composition controls the intranuclear organization of IKZF complexes.
This structural hierarchy was mirrored by marked functional asymmetry. IKZF1 KD produced 228 genes with concordant changes in chromatin accessibility and expression, compared with 12 after IKZF3 KD. IKZF1 loss also generated 5,635 accessibility changes without corresponding immediate transcriptional changes, versus 606 after IKZF3 loss. Combined IKZF1/IKZF3 KD produced 176 concordant genes and 5,694 additional accessibility changes and closely recapitulated IKZF1 KD, demonstrating that IKZF1 determined the magnitude and identity of the response to combined depletion.
IKZF1 KD induced a coherent activation-associated programme across transcriptomic and phenotypic landscape. Concordant chromatin opening and transcriptional upregulation were enriched for leukocyte chemotaxis, migration, and positive regulation of T cell activation and included CCL1, CCL2, IL6, IL9, CD40, MMP12, ITGA9, and ITGB5. Consistent with this programme, flow cytometry demonstrated increased CD25, CD38, and CD127 together with reduced CD45RA and TIM-3 protein expression in IKZF1 KD CD8+ T cells.
IKZF KD simultaneously initiated adaptive family rewiring. IKZF3 KD increased IKZF1, whereas IKZF1 KD induced IKZF3 and IKZF2. Combined IKZF1/IKZF3 KD induced IKZF2 together with increased chromatin accessibility at the IKZF2 locus, identifying IKZF2 as a candidate compensatory node when the principal IKZF1/IKZF3 axis is disrupted.
Conclusions: Therapeutic depletion of IKZF appears to remodel a hierarchically organized, adaptively buffered transcription factor network, suggesting that the targets affected may not all play equivalent functional roles. IKZF1 appears to influence the extent of epigenetic and functional reprogramming in CD8+ T cells, while dimer-dependent nuclear organization and reciprocal family regulation may help shape the overall response. Compensatory induction of IKZF2 could potentially constrain the depth or persistence of this effect. Together, these findings provide new mechanistic insights into the complex regulatory network relevant to IKZF-directed adjuvant strategies across CAR T cell, T cell engager, and other T cell-based cancer immunotherapies.
DISCLOSURES
Gigi Nu Hoang Quy Ton, PhD: No relevant conflicts of interest to declare.